Our products

CNX Therapeutics commercialise and distribute a portfolio of speciality brands and hospital products in over 40 countries worldwide, both directly and through strategic partnerships. These products cover a range of therapeutic areas including CNS, oncology and critical care.

We are seeking to expand our product portfolio and are open to in-licensing, co-promotion, revenue-sharing, and other partnering opportunities.

Please also reach out to us to discuss out-licensing opportunities available for global commercialisation.

CNS

Latuda® (lurasidone) tablets
Cyclizine injection
Magnesium Sulfate injection

Adverse reactions must be reported

Reporting forms and information can be found at yellowcard.mhra.gov.uk.

To report Adverse Reactions:
+44 (0) 20 7821 2899

Oncology

Gemcitabine injection
New oncology products coming soon

Critical Care

Chlorphenamine injection
Doxapram injection
Labetalol injection
Meropenem injection
Dexamethasone oral solution
New critical care products coming soon

Business Development

Dossiers Available

Bortezomib
3.5mg vial
Chlorphenamine
10mg/ml in 1ml
Cyclizine
50mg/ml in 1ml amps
Doxapram
20mg/ml in 1ml amps

Magnesium Sulfate
20% amps 10ml
Pemetrexed
500mg vial
Zoledronic Acid
4mg vial
Zoledronic Acid
5mg vial

In-Licensing

CNX Therapeutics is seeking to expand its product portfolio in Europe and selected global markets.

Our business development activities are focused on approved prescription branded and generic products.

We are open to in-licensing, co-promotion, revenue-sharing, and other partnering opportunities.

We are primarily interested in pharmaceutical products for diseases of the central nervous system, but will consider broader therapy areas if we are able to add value when commercialising.

If you’d like to contact us, please use the form on our Contact page.